Phase II clinical trial of the combination of high-dose toremifene and exemestane for advanced/recurrent breast cancer unresponsive to nonsteroidal aromatase inhibitors
Latest Information Update: 30 Jul 2015
Price :
$35 *
At a glance
- Drugs Exemestane (Primary) ; Toremifene (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 30 Jul 2015 New trial record